anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A system and related techniques generate and track clinical supply orders, policies, individual or aggregate consumption and automated billing, ordering and fulfillment functions via an integrated clinical platform. A patient supply record may be generated for individual patients which traces the consumption of surgical, disposable, pharmaceutical and other supplies throughout a medical encounter or series of encounters or treatment. Physician supply preferences may be aggregated and analyzed to derive value leverage, for instance through volume pricing or conforming department supplies to standard practices. In implementations the supply selections of a given doctor or department or for specified categories of procedure may be analyzed in terms of ultimate patient outcomes resulting from use of those clinical supplies to identify best results and optimize other aspects of clinical operation. A supply chain engine may communicate with supply tracking resources to automatically trigger orders for different supplies, for instance through enterprise resource planning (ERP) or other channels. In embodiments the supplies and materials so ordered may be automatically fulfilled or delivered from the vendor side, for instance based on quantity threshold or closest or most efficient delivery points.
Participants randomised to positive control regimen will be instructed to use the positive cleanser and positive control product twice a day (morning and night). Morning and evening applications should be separated by at least 8 hours. Participants will be instructed to apply the positive control cream immediately after cleansing.
The cohort will be followed for at least 10 years. The cohort will be divided into 2 groups according the pathological results of patients,and at least 3 groups according to clinical features such as renal function and proteinuria.
The present invention relates to a medical data measurement system. The medical data measurement system includes a sensing module and an intelligent module. The sensing module is used for monitoring changes of data. The intelligent module is used for receiving data from the sensing module and includes an identification module and a processing module. The identification module is used to identify and decide to drive the processing module to obtain a physiological value from the data. The sensing module can be used for an automatic forehead temperature measurement. The above invention can achieve the effect of automatic measurement and tracking of medical data.
FIELD: pharmacology; production of neurohormonal drugs, in particular, abbergin. SUBSTANCE: finely divided ergot cornicula of ergocryptic strain are extracted with dichloroethane, followed by thickening dichloroethane extracts by evaporation. Then petroleum ether is added to extracts to precipitate all alkaloids contained therein. Precipitate is dissolved in chloroform and solution is passed through bed of fine-grain sorbent, thickened by evaporation and crystallized from benzene. As a result, mixture of alpha- and beta-ergocryptins is obtained in the form of solvate containing two benzene molecules. Solvate is subjected to bromination by adding to it N-bromosuccinamide at 20 C, followed by stirring solution. Solvents are removed, residue is filtered through silica gel bed in vacuum, thickened by evaporation and crystallized from acetone. Prepared product is isolated in the form of base and then converted into methane sulphonate. EFFECT: higher product yield; simplified process. 2 cl, 1 tbl
There is growing evidence that the protein family of Gasdermins (GSDMs) play an essential role during the progression of colorectal cancer (CRC). However, it is not completely clear that how GSDMB, abundantly expressed in epithelial cells of gastrointestinal tract, regulates the tumorigenesis of CRC. A wealth of evidence linking GSDMB to the pathogenesis of cancer has come from genome-wide association studies. Here, we provide evidence that aberrantly upregulated GSDMB is responsible for suppressing the CRC progression by using in vitro cell and intestinal organoid, as well as in vivo GSDMB transgenic mice models. Mechanistically, GSDMB interacts with insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1), which directly binds to and recognizes the 3'-UTR of dual specificity phosphatase 6 (DUSP6) mRNA, enhances the translation of DUSP6 protein and inhibits downstream ERK phosphorylation, thereby facilitating cell death and restraining cell proliferation. Our results suggest that GSDMB has potential as a novel therapeutic target for CRC treatment.
This is the only arm of the study. The patients will be given yoga videos to do at home for 8 weeks as a treatment for anterior knee pain.
OBJECTIVE: Individuals with chronic pain due to knee osteoarthritis (OA) are insufficiently physically active, and alterations of facilitatory and inhibitory nociceptive signaling are common in this population. Our objective was to examine the association of these alterations in nociceptive signaling with objective accelerometer-based measures of physical activity in a large observational cohort.
DESIGN: We used data from the Multicenter Osteoarthritis Study. Measures of peripheral and central pain sensitivity included pressure pain threshold at the knee and mechanical temporal summation at the wrist, respectively. The presence of descending pain inhibition was assessed by conditioned pain modulation (CPM). Physical activity was quantitatively assessed over 7 days using a lower back-worn activity monitor. Summary metrics included steps/day, activity intensity, and sedentary time. Linear regression analyses were used to evaluate the association of pain sensitivity and the presence of descending pain inhibition with physical activity measures.
RESULTS: Data from 1873 participants was analyzed (55.9% female, age = 62.8 ± 10.0 years). People having greater peripheral and central sensitivity showed lower step counts. CPM was not significantly related to any of the physical activity measures, and none of the exposures were significantly related to sedentary time.
CONCLUSIONS: In this cohort, greater peripheral and central sensitivity were associated with reduced levels of objectively-assessed daily step counts. Further research may investigate ways to modify or treat heightened pain sensitivity as a means to increase physical activity in older adults with knee OA.
Recent advances in genetic diagnosis have revealed the underlying etiology of many epilepsies and have identified pathogenic, causative variants in numerous ion and ligand-gated channel genes. This chapter describes the clinical presentations of epilepsy associated with different channelopathies including classic electroclinical syndromes and emerging gene-specific phenotypes. Also discussed are the archetypal epilepsy channelopathy, SCN1A-Dravet syndrome, considering the expanding phenotype. Clinical presentations where a channelopathy is suspected, such as sleep-related hypermotor epilepsy and epilepsy in association with movement disorders, are reviewed. Channelopathies pose an intriguing problem for the development of gene therapies. Design of targeted therapies requires physiologic insights into the often multifaceted impact of a pathogenic variant, coupled with an understanding of the phenotypic spectrum of a gene. As gene-specific novel therapies come online for the channelopathies, it is essential that clinicians are able to recognize epilepsy phenotypes likely to be due to channelopathy and institute early genetic testing in both children and adults. These findings are likely to have immediate management implications and to inform prognostic and reproductive counseling.
FIELD: organic chemistry, biochemistry, medicinal chemistry, pharmacy. SUBSTANCE: invention relates to methods for modulation of function of serine/threonine-protein kinases with 5-azaquinoxaline-base compounds. Methods involve using cells expressing serine/threonine-protein kinase, such as RAF. Except for, invention describes methods for prophylaxis and treatment associated with disturbances in metabolism of serine/threonine-protein kinase in pathological states in body using compound defined in the invention. Invention relates also to 5- azaquinoxaline-base compounds and pharmaceutical compositions comprising these compounds. EFFECT: expanded assortment of agents regulating function of serine/threonine-protein kinase. 40 cl, 4 tbl, 7 ex
In the prodn. of a composite material with prolonged release of a physiologically active substance enclosed therein, a system comprising one or more polypeptides, one or more proteins and one or more physiologically active substances in the frozen state is ground to particles and mechanically mixed, the mixture is brought into a suitable form, and the formed pieces are compressed to a suitable shape under a pressure in the range of 100-20000 kg/sq.cm. In a further new process for the prodn. of a prolonged release composite material, an intimate mixture of one or more N-carboxy amino acid anhydrides and one or more physiologically active substances is brought into a suitable form at -20 to plus 40 deg.C. under a pressure of 10-20000 kg/sq.cm. In an additional new process for the prodn. of a prolonged release composite material, a system comprising one or more polypeptides, one or more proteins, one or more physiologically active substances and a suitable mixture of water and an organic solvent is brought into a suitable form and the formed pieces are warmed to between room temp. and 100 deg.C. Prodn. of prolonged release preparations, e.g. tissue-implants contg. physiologically active substances, such as the antitumour agents 5-FU, bleomycin or nitomycin C, testosterone, or agrochemicals.
Patients receive standard of care cyclophosphamide IV over 30 minutes and fludarabine IV over 30 minutes on days -5, -4, and -3, and then receive CD19-CD22 CAR T cells IV on day 0. Patients with relapsed or persistent disease after a protocol assessment may receive a second infusion of CD19-CD22 CAR T cells.
Preterm infants are supplemented with PreNAN FM85 as fortifier to human milk. PreNAN FM85 contains partially hydrolyzed protein and maltodextrin including vitamins and minerals. The product is supplied in a powdered form.
During the intervention period, staff will capture women during the first well-baby visit (WBV) and offer to have the next visit co-scheduled for infant and contraception care. Appointments are scheduled during the discharge process at the end of each WBV. During the discharge process all women 0-6 months postpartum will be identified by clerical staff through review of each pediatric clinic beforehand and through an electronic flag alert in the infant's electronic medical record. The pre-review of pediatric clinic schedules and the use of the flag will remind staff to offer the mother a co-scheduled visit for newborn and contraceptive care at the time of the next newborn visit.
1278817 Coutrolled-release medicaments G S BANKER and H GOODMAN 2 Sept 1969 [3 Sept 1968] 43480/69 Heading A5B [Also in Division C3] Orally administrable, sustained release compositions comprise a drug chemisorbed on the particles of a latex of a polymer which is hydratable in the gastro intestinal tract, the polymer containing acid groups of the drug is basic and basic groups if the drug is acidic. Suitable polymers are those formed by emulsion polymerisation of aqueous emulsions of the monomers listed in Specification 1278816. The product may be used as such in a liquid preparation or the polymer particles may be removed from suspension e.g. by filtration, centrifugation, spray-drying &c, either with or without initial flocculation as by addition of an electrolyte. Specific examples relate to preparations in which the drug is methapyrilene HCl. chlorpheniramine (base), chlorpromazine (HCl and benzoate) and codeine (base and phosphate), the resins being acrylic-copolymers having carboxylic acid groups.
PURPOSE: Recently, many studies revealed that frailty affects unfavorably on postoperative outcomes in lumbar spinal diseases. This study aimed to investigate the relationship between frailty and clinical outcomes while identifying risk factors associated with worse clinical outcomes following lumbar spinal surgery.
METHODS: From March 2019 to February 2021, we prospectively enrolled eligible patients with degenerative lumbar spinal diseases requiring surgery. Frailty was assessed preoperatively. To identify the impact of frailty on lumbar spinal diseases, clinical outcomes, which were measured with patient-reported outcomes (PROs) and postoperative complications, were compared according to the frailty. PROs were assessed preoperatively and one year postoperatively. In addition, risk factors for preoperative and postoperative worse clinical outcomes were investigated.
RESULTS: PROs were constantly lower in the frail group than in the non-frail group before and after surgery, and the change of PROs between before and after surgery and postoperative complications were not different between the groups. In addition, frailty was a persistent risk factor for postoperative worse clinical outcome before and after surgery in lumbar spinal surgery.
CONCLUSION: Frailty persistently affects the clinical outcome negatively before and after surgery in lumbar spinal surgery. However, as the change of the clinical outcome is not different between the frail group and the non-frail group, it is difficult to interpret whether the frail patients are vulnerable to the surgery. In conclusion, frailty is not an independent risk factor for worse clinical outcome in lumbar spinal surgery.
Participants: Women (n=24; 18-55 y) with a BMI \> 25 and \< 35 kg·m-2 who are sedentary to moderately active were recruited to participate. Research Design: This study was a randomized, counter-balanced, cross-over clinical trial consisting of three experimental conditions in which each participant served as her/his own control. Assessments of health history, physical activity (to confirm that participants were physically inactive), anthropometrics, resting metabolic rate, and aerobic capacity were made during an initial laboratory visit. Participants performed three different study conditions, typically separated by one week, thus women were not tested in a specific menstrual cycle phase. Participants recorded their diet the day before and the morning of the first condition and replicated this for the second and third conditions. On the study days, participants consumed their breakfast prior to 9:00 AM and arrived in the lab at 11 AM. The three conditions were performed in randomized order. In the control condition (CON), participants rested quietly for 1 hour. In the remaining two conditions, participants performed 45 minutes of treadmill exercise at 11 AM. Following the rest or exercise period, subjects were provided energy balanced diets. Total energy intake was balanced across exercise conditions and appropriately adjusted for the lack of exercise in the CON condition. At 7 AM on the following morning, following an overnight fast, an oral glucose tolerance test (OGTT) was performed. Measurements were made to determine fasting glucose, insulin and lipid panel, 2-hour OGTT glucose, insulin sensitivity (SI OGTT), early (0-30 min) and late (30-120 min) glucose stimulated insulin secretion (GSIS) based on c-peptide concentrations. Indirect calorimetry was also performed to determine resting carbohydrate and fat oxidation and metabolic flexibility, defined as the change in respiratory exchange ration (RER) during the OGTT. Interleukin-6, tumor necrosis factor-alpha, and reactive oxygen species were measure before, 60, and 120 minutes during the OGTT to assess the inflammation response.
Colonoscopy is performed with the unassisted colonoscope. The stiffening wire is introduced only if there is difficulty advancing the colonoscope and only after the tip has passed the splenic flexure. Difficulty is defined as failure to advance the tip of the scope after 5 minutes of trying.
Reversible elevations in serum transaminases (ALT or AST) have been observed during treatment with carvedilol. Rates of transaminase elevations (2- to 3-times the upper limit of normal) observed during controlled clinical trials have generally been similar between patients treated with carvedilol and those treated with placebo. However, transaminase elevations, confirmed by rechallenge, have been observed with carvedilol. In a long-term, placebo-controlled trial in severe heart failure, patients treated with carvedilol had lower values for hepatic transaminases than patients treated with placebo, possibly because improvements in cardiac function induced by carvedilol led to less hepatic congestion and/or improved hepatic blood flow. 

Carvedilol has not been associated with clinically significant changes in serum potassium, total triglycerides, total cholesterol, HDL cholesterol, uric acid, blood urea nitrogen, or creatinine. No clinically relevant changes were noted in fasting serum glucose in hypertensive patients.
The 8-week prehabilitation program will be delivered online using synchronous and asynchronous sessions delivered by either a physiotherapist, chiropractor or kinesiologist. There will be 4 individual exercises sessions delivered synchronously using Zoom or Physitrack in which motivational interviewing and graded activity exercises will be conducted. Participants will also be asked to exercise at least 3 times a week using the asynchronous exercise videos. The exercises will be individualized on participants functional ability and personal goals identified at baseline, with a focus on muscle strengthening, stretching, improving spinal flexibility and stability. There will be a booster session at 6-weeks post-op. Participants will also undergo 5 group educational sessions, which will provide information regarding: goal setting, pain education, self-management, pacing, post-operative expectations, exercise recommendations, and information regarding their upcoming surgery.
Routine Care is described in detail in Couch, SC et al. Hypertension 2021: 77:241-251.
In each intensive care unit assigned to the Control-then-Intervention arm, all participants who regularly access the ICUs will wear the wristband while at work for 5 months. The functionality of the wristband will not be disclosed to the healthcare providers. Handwashing compliance data will be automatically collected, but data will not be shared with the healthcare providers or hospital management teams. After 5 months, a washout period of 2 months will be introduced to eliminate potential influences on healthcare providers' behaviors from the sensor system. Then, all healthcare providers will be educated on the functionalities of the CleanHands system with real time reminders now turned on. Healthcare providers will then have access to their own and unit-specific handwashing data. The unit manager and hospital administrators will be able to access all of these data and advanced analysis to make management decisions on infection reduction. This phase will last for 5 months.
A silica particle for medical imaging includes a bridged silane fluorescent dye incorporated throughout the particle matrix. Copolymerization of a bridged silane fluorescent dye (e.g., (R′O) 3 Si—R—Si(OR′) 3 , where R is a fluorescent organic bridging group, and where R′ is a methyl or ethyl group) and a tetralkoxysilane (e.g., Si(OR′) 4 , where R′ is a methyl or ethyl group) generates particles of a predetermined size and shape. This leaves the surface of each particle available for further modification to facilitate dispersion of the particle into different media. Hence, a surface modifier may be subsequently bonded onto the particle surface. In some embodiments, poly(ethylene glycol) is selected as the surface modifier to increase dispersion of the silica particle in an aqueous media. In some embodiments, the particle is porous allowing for an additional functionality (e.g., a secondary imaging material, such as magnetic nanoparticles, and/or a pharmaceutical drug) to be loaded within the pores.
Patients treated with SAGB by solicited teams. No selection criteria at cohort inclusion applied to the 500 (+50) first patients treated in order to ensure consecutive and exhaustive recruitment in the concerned centers over the inclusion period.
It is well established that functional exercise capacity and peak oxygen uptake (VO2) are reduced in patients with type 2 diabetes mellitus (T2DM) compared with healthy counterparts. The mechanisms underlying the exercise deficit in T2DM remain largely unknown, but previous work has suggested that reduced exercise blood flow and impaired submaximal VO2 may be contributing factors. Both of these findings are consistent with a peripheral impairment of skeletal muscle oxygen delivery, oxygen utilization, or both. Indeed, dysfunction of skeletal muscle metabolism plays a key role in the pathophysiology of T2DM, and considerable work has described abnormalities of oxidative function in the skeletal muscle of people with T2DM. Given this, it is likely that the causes of exercise intolerance in T2DM may relate to specific defects at the level of the skeletal muscle, particularly given that skeletal muscle blood flow and oxidative capacity are impaired in diabetes. However, to the knowledge of the investigators, no one has related these peripheral muscle abnormalities to the diminished exercise function in this patient group.

The overarching hypothesis for the proposed research is that impaired CVEC in T2DM is the result of preclinical cardiac, vascular dysfunction and skeletal muscle perfusion abnormalities. Exercise training will improve CVEC and will reveal specific reversible therapeutic aspects of this pathology. The investigators will first determine the impairments and then evaluate responses to an established cardiac rehabilitation exercise training program, established to improve fitness in people with and without diabetes. Given the greater CVEC abnormalities observed in women, sex differences will be evaluated for each aim.
LONG TERM OXYGEN THERAPY IN CHRONIC RESPIRATORY DISEASES. Survival of severe chronic respiratory failure with chronic obstructive pulmonary disease (COPD) is improved by long-term oxygen therapy. Other benefits exist for COPD and other causes of chronic respiratory failure. The indications for this restrictive (more 15 hours per day) treatment require measurements of arterial blood gases in adults. Several actors are involved: the specialist for the prescription, the service provider for supplying and maintaining the equipment, the patient and his entourage, the referring doctor to ensure that oxygen therapy is well tolerated and used. The referring doctor can prescribe short-term oxygen therapy for transient respiratory failure. The choice of oxygen source depends on the patient's ability to ambulate and the required flow rate. Concentrators are increasingly used, despite limited flow rate with mobile devices. Liquid oxygen makes it possible to deliver high flow rates but is expensive. The main complications of oxygen therapy are the worsening of chronic hypercapnia, burns (especially in active smokers)...